Microbix Biosystems (TSE:MBX) Hits New 1-Year High – What’s Next?

Microbix Biosystems Inc. (TSE:MBX) hit a new 52-week high on Wednesday . The company traded as high as C$0.32 and last traded at C$0.31, with a volume of 22000 shares traded. The stock had previously closed at C$0.31.

Microbix Biosystems Stock Down 6.3%

The company has a market capitalization of C$41.25 million, a P/E ratio of -7.32 and a beta of 0.72. The company has a quick ratio of 5.57, a current ratio of 5.35 and a debt-to-equity ratio of 27.03. The firm has a fifty day simple moving average of C$0.30 and a 200-day simple moving average of C$0.26.

Microbix Biosystems (TSE:MBX) last issued its earnings results on Thursday, August 13th. The company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$4.06 million for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%. On average, equities research analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Microbix Biosystems news, Director Martin Marino purchased 115,000 shares of the stock in a transaction on Thursday, May 28th. The shares were purchased at an average price of C$0.28 per share, with a total value of C$32,200.00. Following the completion of the transaction, the director directly owned 2,000,167 shares in the company, valued at C$560,046.76. This represents a 6.10% increase in their ownership of the stock. Insiders bought a total of 251,000 shares of company stock worth $68,355 in the last three months. Company insiders own 14.00% of the company’s stock.

About Microbix Biosystems

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.